We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Expert Opinion / Interview · July 25, 2013

Anticoagulation in Pacemaker-Detected Atrial Fibrillation and the New Oral Anticoagulants

Written by
Stuart J Connolly MD, FRCPC


Additional Info

  1. Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med. 2012;366(2):120-129.

  2. Agnelli G, Buller HR, Cohen A, et al. Apixaban for Extended Treatment of Venous Thromboembolism [published online ahead of print December 8, 2012]. N Engl J Med. doi: 10.1056/NEJMoa1207541.

  3. Connolly SJ. Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-able Double-blind Randomized Trial. Paper presented at: American Heart Association 2012 Scientific Sessions; November 4-6, 2012; Los Angeles, California. Session CS.04.

Further Reading